Lachman has been providing
both onsite and remote
support to our clients
for many years.

Review Support Offerings
The Lachman Difference

The most efficient services.
The most qualified professionals.

Since 1978, Lachman Consultants’ multidisciplinary team of highly experienced FDA consultants and industry experts has offered compliance, regulatory affairs, and science & technology services to clients around the world.

Learn More About Us

Stay in the know

Sign up today for the Lachman Consultants blog.

Get the latest news on industry compliance, regulatory affairs, technical services, and a whole lot more.

    Lachman Practice Groups

    Three Practices
    Executing One Vision

    Lachman Consultants maintains three practice groups: Compliance, Regulatory Affairs, and Science and Technology. Each practice offers industry-leading experience and expertise in its area of focus.

    Lachman OnCall Logo

    Get the answers and guidance to your most pressing questions faster than ever before.

    Now you can speak to one of our Subject Matter Experts and get the answers you need quickly on the many pressing issues arising in the life science areas that Lachman Consultants serves on a day to day basis. Whether it’s something you need to know about compliance, or a complex scientific or technical issue, Lachman OnCall™️ can provide you the timely information you require as needs arise and unforeseen questions occur.

    Learn More About Lachman OnCall

    OnCall Image

    Recent Posts

    The Lachman Consultants Blog

    The latest on industry compliance, regulatory affairs, technical services, and a whole lot more.

    Blackboard Business Strategy Concept

    Peek at the January 2022 Approval Actions

    With ANDA reporting through January 21, 2022, the OGD has issued thirt...
    Read More

    OGD First FY 2022 Quarterly Report Contains Some “Interesting” Numbers

    The Activities Report of the Generic Drugs Program | GDUFA II Quarterl...
    Read More

    Official December 2022 ANDA Approvals, CRLs, and Receipts Hit the Web

    We hit the number of December full‑approval actions on the head (thi...
    Read More

    Saving the Skinny Label: Could Another Case Bring It Off the Respirator?

    This morning, Sara W. Koblitz of Hyman, Phelps & McNamara posted a...
    Read More

    CDER Issues Report on Novel Therapy Approvals for 2021

    The Center for Drug Evaluation and Research (CDER) approved 50 novel t...
    Read More

    And Just Like That – The November Numbers Appear!

    While it has been over a full month waiting for official approval numb...
    Read More
    Contact Us Today